Plasma Nesfatin-1 Level in Relation to Dyslipidemia and VEGF-A with Poor Control Type 2 Diabetes Mellitus

Authors

  • Alaa A Mahmoud *, Ahmed A Mohsin ,Walaa E Jassim Department of Medical Laboratory Technologies- College of Health and Medical Techniques /Baghdad, Middle Technical University, Baghdad, Iraq

Keywords:

Nesfatin-1, dyslipidemia, angiogenesis, Diabetes mellitus type 2, VEGF-A

Abstract

NUCB2/nesfatin-1 plays a role in physiological regulation, it provides you with energy and stimulates the development of brown adipocytes through a pathway and increased expression. In the pathophysiology of diabetes mellitus, the vascular endothelial growth factors A(VEGF-A) is of critical importance. The aim of this study to assessment level of nesfatin-1, lipid profile and VEGF-A in a group of patients with poor control type 2 diabetes mellitus (T2DM) and compare it with apparently healthy control and study the correlation with each other’s. There were 180 participants in the research study,70 control persons and 110 T2DM patients. Serum cholesterol, triglyceride, HDL and LDL were calculated by COBAS INTEGRA 400 plus. Nesfatin-1 and VEGF-A levels were estimated using enzyme-linked immunosorbent assay(ELISA) kit. The levels of Nesfatin-1 and VEGF-A in the patients group and in the normal control found to differ significantly (p < 0.001). Significant positive correlation was seen between the level of Nesfatin-1 and VEGF-A (P <0.001) .Non-significant correlation was found between Nesfatin-1 and VEGF-A with each of serum cholesterol, triglyceride,high density lipoprotein(HDL), and low density lipoproteins(LDL) in patients with poor control diabetes (p> 0.05) . In conclusion, the correlation between VEGF-A and nesfatin-1 indicating that Nesfatin-1 levels rise in tandem with VEGF-A levels. The absence of correlation between Nesfatin-1 and VEGF-A with lipid abnormalities demonstrate that lipid problems related to diabetes could not affect how angiogenesis is regulated.

References

Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg. 2003;58(6):335–341.

Schalla, M. A., & Stengel, A. (2018). Current understanding of the role of nesfatin-1. Journal of the endocrine society, 2(10), 1188-1206.

Jiang, G., Wang, M., Wang, L., Chen, H., Chen, Z., Guo, J., Weng, X., Liu, X., 2015. The Protective effect of nesfatin-1 against renal ischemia-reperfusion injury in rats. Ren.Fail. 37, 882-889.

Wang Z, Chen S, Zou X, Tian L, Sui S, Liu N. Nesfatin-1 alleviates acute lung injury through reducing inflammation and oxidative stress via the regulation of hmgb1. Eur Rev Med Pharmacol Sci. 2020;24:5071-5081

protects dopaminergic neurons against MPP+/MPTP-induced neurotoxicity through the CRaf-ERK1/2-dependent anti-apoptotic pathway. Sci. Rep. 7, 40961.

Skóra, J., Biegus, J., Pupka, A., et al., 2006. Molecular basics of angiogenesis. Postepy Hig. Med. Dosw., 60:410-415(in Polish).

Kim, H.N., Oh, H.J., Seo, A.J., et al., 2005. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int., 67(1):167-177.

Palazhy S, Viswanathan V. Lipid abnormalities in type 2 diabetes mellitus patients with overt nephropathy. Diabetes Metab J. 2017;41(2):128.

Bekele S, Yohannes T, Mohammed AE. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region. Diabetes Metab Syndr Obes Targets Ther. 2017;10:265.

Zhai, T., Li, S. Z., Fan, X. T., Tian, Z., Lu, X. Q., & Dong, J. (2017). Circulating nesfatin-1 levels and type 2 diabetes: a systematic review and meta-analysis. Journal of diabetes research, 2017.

Al-Masoudi, F. I., & Ali, B. H. (2021). Evaluation of Nesfatin–1 and Other Biochemical Markers in diabetic Neuropathy Iraqi patients before and after treatment with tegretol. Annals of the Romanian Society for Cell Biology, 9422-9429.

Aydin,S.(2013). Multi-functional peptide hormone NUCB2/nesfatin-1. Endocrine, 44, 312-325.

Asselbergs FW, de Boer RA, Diercks GF, et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004;93:211–5.

Basia, D., Kulhria, A., & Tandon, R. Correlation of Oxidative Stress Markers, Antioxidants, Vegf and Apoa-I in Patients of Type 2 Diabetes Mellitus without Retinopathy. Age (in years), 50(9.132), 52-35.

Morris S, Cholan PM, Britton WJ, Oehlers SH. Glucose inhibits haemostasis and accelerates diet-induced hyperlipidaemia in zebrafish larvae. Sci Rep. 2021 Sep 24;11(1):19049.

Abdissa, D., & Hirpa, D. (2022). Dyslipidemia and its associated factors among adult diabetes outpatients in West Shewa zone public hospitals, Ethiopia. BMC Cardiovascular Disorders, 22(1), 1-8.

Hasnat, M. A., Niloy, F. R., Ashik, A. I., Hasan, M., Dev, P. C., Panna, S. S., ... & Hasan, Z.(2022) Prevalence of hyperlipidemia in controlled and uncontrolled type-2 diabetic patients. system, 22, 23.

Jonathan D. Schofield, Yifen Liu, Prasanna Rao-Balakrishna, Rayaz A. Malik, and Handrean Soran. Diabetes Dyslipidemia. 2016 Jun; 7(2): 203–219.

Downloads

Published

2023-02-23

How to Cite

Alaa A Mahmoud *, Ahmed A Mohsin ,Walaa E Jassim. (2023). Plasma Nesfatin-1 Level in Relation to Dyslipidemia and VEGF-A with Poor Control Type 2 Diabetes Mellitus. International Journal of Scientific Trends, 2(2), 74–79. Retrieved from https://scientifictrends.org/index.php/ijst/article/view/55

Issue

Section

Articles